Journal List > Ewha Med J > v.35(2) > 1058551

TOOLS
Choi: Drug Eruption
Review Article
The Ewha Medical Journal

The Ewha Medical Journal 2012; 35(2): 76-82.

Published online: 30 September 2012

DOI: https://doi.org/10.12771/emj.2012.35.2.76

Drug Eruption

You Won Choi

Department of Dermatology, Ewha Womans University School of Medicine, Seoul, Korea.

Corresponding author: You Won Choi, Department of Dermatology, Ewha Womans University School of Medicine, 1071 Anyangcheon-ro, Yangcheon-gu, Seoul 158-710, Korea. Tel: 82-2-2650-5159, Fax: 82-2-2652-6925, uwon313@ewha.ac.kr

Copyright © 2012. Ewha Womans University School of Medicine

Abstract

Drug eruptions are common problems in hospital inpatients and outpatients. Cutaneous drug reactions range from mild to severe and from those localized only to skin to those associated with systemic disease. Cutaneous drug reactions are also a challenging diagnostic problem since they can mimic a large variety of skin diseases, including viral exanthem, collagen vascular disease, neoplasia, bacterial infection, psoriasis, and autoimmune blistering disease, among others. Furthermore, determining a particular medication which caused an eruption is often difficult when the patient is taking multiple drugs. In this review, clinical manifestations of adverse cutaneous drug reactions are described. A morphologic approach to drug eruption includes those that are classified as exanthematous eruption, urticaria, pustular eruption, bullous eruption, fixed drug eruption, photosensitive eruption, skin necrosis, lichenoid eruption, cutaneous pseudolymphoma, lupus erythematosus, and hand-foot syndrome. And also, recently reported cutaneous adverse reactions associated with newly developed drugs, such as epidermal growth factor receptor inhibitors, low molecular weight tyrosine kinase inhibitors, tumor necrosis factor-alpha antagonists, sirolimus and granulocyte colony-stimulating factor, are discussed.

Keywords: Cutaneous, Drug eruption, Morphology

References

1. Arndt KA, Jick H. Rates of cutaneous reactions to drugs: a report from the Boston Collaborative Drug Surveillance Program. JAMA. 1976. 235:918–923.
2. DeSwarte RD. Drug allergy: problems and strategies. J Allergy Clin Immunol. 1984. 74:209–224.
3. Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ. Fitzpatrick's dermatology in general medicine. 2008. 7th ed. New York: McGraw-Hill Medical Publishing.
4. Barbaud A, Gonçalo M, Bruynzeel D, Bircher A. European Society of Contact Dermatitis. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis. 2001. 45:321–328.
5. Barbaud A, Reichert-Penetrat S, Tréchot P, Jacquin-Petit MA, Ehlinger A, Noirez V, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol. 1998. 139:49–58.
6. Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol. 2003. 4:561–572.
7. Revuz J, Valeyrie-Allanore L. Bolognia JL, Jorizzo JL, Rapini RP, editors. Drug reactions. Dermatology. 2003. St. Louis: Mosby;333–353.
8. Josephs SH, Rothman SJ, Buckley RH. Phenytoin hypersensitivity. J Allergy Clin Immunol. 1980. 66:166–172.
9. Lee AY. Drug eruption probably caused by penicillin in milk. Korean J Dermatol. 1986. 24:514–517.
10. Ros AM, Juhlin L, Michaëlsson G. A follow-up study of patients with recurrent urticaria and hypersensitivity to aspirin, benzoates and azo dyes. Br J Dermatol. 1976. 95:19–24.
11. Rappersberger K, Hönigsmann H, Ortel B, Tanew A, Konrad K, Wolff K. Photosensitivity and hyperpigmentation in amiodarone-treated patients: incidence, time course, and recovery. J Invest Dermatol. 1989. 93:201–209.
12. Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. Drug Saf. 2011. 34:821–837.
13. Shin KS, Cho KH, Lee YS. Clinical study of hospitalized patients with drug eruption during a 10-year reriod (1975~1985). Korean J Dermatol. 1987. 25:176–182.
14. Katz U, Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev. 2010. 10:46–50.
15. Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol. 2011. 50:619–625.
16. Kwon TE, Kwon OS, Chung JH, Cho KH, Youn JI. A clinicopathological study of chronic cutaneous lupus erythematosus. Korean J Dermatol. 1999. 37:459–467.
17. Adachi A, Nagai H, Horikawa T. Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions. Dermatology. 2007. 214:85–88.
18. Suwattee P, Chow S, Berg BC, Warshaw EM. Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis. Arch Dermatol. 2008. 144:123–125.
19. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005. 6:491–500.
20. Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 2006. 12:131–141.
21. Sung KJ, Jeong HG, Koh JK. Erythrodysesthesia syndrome due to fluorouracil. Korean J Dermatol. 1990. 28:450–455.
22. Suh EJ, Kim SH, Kim SW. A case of excess granulation tissue response during etretinate therapy. Korean J Dermatol. 1986. 24:464–468.
23. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005. 16:1425–1433.
24. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007. 56:317–326.
25. Tang PA, Tsao MS, Moore MJ. A review of erlotinib and its clinical use. Expert Opin Pharmacother. 2006. 7:177–193.
26. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006. 55:657–670.
27. Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA) monotherapy: clinical experience in non-small-cell lung cancer. Drug Saf. 2004. 27:1081–1092.
28. Pérez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park). 2003. 17:23–28.
29. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004. 351:337–345.
30. Jang YH, Choi JH, Lim HY, Lee ES. Study of clinical features of cutaneous side effects associated with ZD 1839. Korean J Dermatol. 2005. 43:22–28.
31. Chung WK, Chang SE, Ryu MH, Lee MW, Choi JH, Moon KC, et al. Clinical features of the cutaneous adverse events induced by combination chemotherapy that includes cetuximab (Erbitux®). Korean J Dermatol. 2008. 46:1478–1487.
32. Chang GC, Yang TY, Chen KC, Yin MC, Wang RC, Lin YC. Complications of therapy in cancer patients. Case 1: paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004. 22:4646–4648.
33. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001. 344:1031–1037.
34. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002. 99:1928–1937.
35. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol. 2003. 48:201–206.
36. Hsiao LT, Chung HM, Lin JT, Chiou TJ, Liu JH, Fan FS, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol. 2002. 117:620–622.
37. Brouard MC, Prins C, Mach-Pascual S, Saurat JH. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. Dermatology. 2001. 203:57–59.
38. Konstantopoulos K, Papadogianni A, Dimopoulou M, Kourelis C, Meletis J. Pityriasis rosea associated with imatinib (STI571, Gleevec). Dermatology. 2002. 205:172–173.
39. Dalmau J, Peramiquel L, Puig L, Fernández-Figueras MT, Roé E, Alomar A. Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect. Br J Dermatol. 2006. 154:1213–1216.
40. Bae YI, Yun SJ, Lee JB, Kim SJ, Lee SC, Won YH. A case of psoriasiform drug eruption induced by imatinib mesylate (Gleevec™). Korean J Dermatol. 2009. 47:722–725.
41. Assouline S, Laneuville P, Gambacorti-Passerini C. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med. 2006. 354:2623–2624.
42. Ugurel S, Hildenbrand R, Dippel E, Hochhaus A, Schadendorf D. Dose-dependent severe cutaneous reactions to imatinib. Br J Cancer. 2003. 88:1157–1159.
43. Rule SA, O'Brien SG, Crossman LC. Managing cutaneous reactions to imatinib therapy. Blood. 2002. 100:3434–3435.
44. Gupta AK, Skinner AR. A review of the use of infliximab to manage cutaneous dermatoses. J Cutan Med Surg. 2004. 8:77–89.
45. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003. 98:1315–1324.
46. Momin SB, Peterson A, Del Rosso JQ. A status report on drug-associated acne and acneiform eruptions. J Drugs Dermatol. 2010. 9:627–636.
47. Mota A. Sirolimus: a new option in transplantation. Expert Opin Pharmacother. 2005. 6:479–487.
48. Wakefield PE, James WD, Samlaska CP, Meltzer MS. Colony-stimulating factors. J Am Acad Dermatol. 1990. 23:903–912.
49. Asnis LA, Gaspari AA. Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol. 1995. 33:393–410.
50. Aubin F, Dufour MP, Angonin R, Misery L, Laurent R, Humbert P. Sweet's syndrome associated with cutaneous T cell lymphoma. Eur J Dermatol. 1998. 8:178–179.
51. Ross HJ, Moy LA, Kaplan R, Figlin RA. Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment. Cancer. 1991. 68:441–443.
52. Jain KK. Cutaneous vasculitis associated with granulocyte colony-stimulating factor. J Am Acad Dermatol. 1994. 31:213–215.
53. Ostlere LS, Harris D, Prentice HG, Rustin MH. Widespread folliculitis induced by human granulocyte-colony-stimulating factor therapy. Br J Dermatol. 1992. 127:193–194.
54. Alvarez-Ruiz S, Peñas PF, Fernández-Herrera J, Sánchez-Pérez J, Fraga J, García-Díez A. Maculopapular eruption with enlarged macrophages in eight patients receiving G-CSF or GM-CSF. J Eur Acad Dermatol Venereol. 2004. 18:310–313.
55. Mössner R, Beckmann I, Hallermann C, Neumann C, Reich K. Granulocyte colony-stimulating-factor-induced psoriasiform dermatitis resembles psoriasis with regard to abnormal cytokine expression and epidermal activation. Exp Dermatol. 2004. 13:340–346.
56. Prendiville J, Thiessen P, Mallory SB. Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (G-CSF) therapy. Pediatr Dermatol. 2001. 18:417–421.
57. Dereure O, Bessis D, Lavabre-Bertrand T, Exbrayat C, Fegueux N, Biron C, et al. Thrombotic and necrotizing panniculitis associated with recombinant human granulocyte colony-stimulating factor treatment. Br J Dermatol. 2000. 142:834–836.
58. Johnson ML, Grimwood RE. Leukocyte colony-stimulating factors: a review of associated neutrophilic dermatoses and vasculitides. Arch Dermatol. 1994. 130:77–81.
TOOLS
Similar articles